Titre | | nb de chargement | |
---|
Transgene Announces Upcoming Investor Meetings | | 1311 | |
Transgene annonce ses prochaines rencontres avec les investisseurs | | 1288 | |
All of Transgene's preclinical and clinical assets progressed in line with expectations in Q1 2022 | | 1480 | |
Progression de tous les produits précliniques et cliniques de Transgene au premier trimestre 2022 | | 2438 | |
Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination | | 1208 | |
Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination | | 1208 | |
Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | | 1230 | |
Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | | 1230 | |
Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050 | | 5884 | |
Transgene présente de nouvelles données préliminaires de Phase I confirmant le potentiel de TG4050 au congrès de l'AACR 2022 | | 4246 | |
Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | | 3561 | |
Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF | | 3561 | |
Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF | | 3561 | |
Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | | 3561 | |
Availability of Transgene's 2021 Universal Registration Document | | 4495 | |
Mise à disposition du document d'enregistrement universel 2021 de Transgene | | 4143 | |
Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022 | | 4323 | |
Mise à disposition des documents préparatoires à l'Assemblée générale du 25 mai 2022 | | 4059 | |
Transgene's Board of Directors strengthens its governance and proposes the appointment of Dr. Alessandro Riva as Independent Chairman | | 6499 | |
Le conseil d'administration de Transgene renforce sa gouvernance et propose la nomination du Dr Alessandro Riva en qualité de Président Indépendant | | 4090 | |
Transgene confirms the potential of its two innovative platforms and expects significant clinical results in 2022 | | 17404 | |
Transgene confirme le potentiel de ses deux plateformes innovantes et attend des résultats cliniques significatifs en 2022 | | 5291 | |
Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022 | | 8752 | |
Transgene et BioInvent présenteront un poster à l'AACR 2022 sur BT-001, un virus oncolytique innovant | | 5242 | |
Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022 | | 7011 | |
Transgene présentera des nouvelles données préliminaires positives des Phases I avec TG4050 à l'AACR 2022 | | 5467 | |
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment | | 4727 | |
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment | | 4727 | |
Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject "cold" tumors | | 4727 | |
Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject "cold" tumors | | 4727 | |
Éthique et conformité | | 4727 | |
Corporate governance | | 4727 | |
Ethics & compliance | | 4727 | |
Transgene appoints Steven Bloom as Chief Business Officer | | 9603 | |
Transgene annonce la nomination de Steven Bloom au poste de Directeur du Business Development | | 5269 | |
Ethics and compliance | | 4727 | |
Éthique & conformité | | 4727 | |
Custom Styles | | 4729 | |
Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors | | 4733 | |
Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject cold tumors | | 4733 | |
Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade | | 7237 | |
Transgene et BioInvent publient dans le JITC des données de preuve de concept préclinique du virus oncolytique BT-001 | | 6909 | |
| | 4733 | |
Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors | | 13533 | |
Transgene et PersonGen annoncent une collaboration pour l'évaluation d'une nouvelle combinaison thérapeutique contre les tumeurs solides | | 11307 | |
Transgene announces Financial Calendar for 2022 | | 5490 | |
Transgene présente son calendrier de communication financière pour 2022 | | 5852 | |
Biomed Event - Paris | | 7945 | |
Biomed Event - Paris | | 7945 | |
Biotech Showcase Investor Conference Digital- January 17 to 19, 2022 | | 7945 | |
Biotech Showcase Investor Conference Virtuel - 17 au 19 janvier 2022 | | 7945 | |
Biotech Showcase Investor Conference, in conjunction with the J.P. Morgan Healthcare conference - Digital - January 10 to 12, 2022 | | 7945 | |
Biotech Showcase Investor Conference, en parallèle de la conférence annuelle J. P. Morgan - Virtu - 10 au 12 janvier 2022 | | 7945 | |
25th ODDO BHF Digital Forum - Digital - January 6, 7, 10 and 11, 2022 | | 7945 | |
11ème édition du LifeSci Advisors Corporate Access Event - Virtuel - 5 au 7 janvier 2022 | | 7945 | |
11th Annual LifeSci Advisors Corporate Access Event - Digital - January 5 to 7, 2022 | | 7945 | |
ODDO BHF Digital Forum - Virtuel - 6, 7, 10 et 11 janvier 2022 | | 7945 | |
Transgene announces investor Meeting for January 2022 | | 8546 | |
Transgene annonce ses rencontres avec les investisseurs en janvier 2022 | | 10002 | |
License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Invir.IO Platform | | 7945 | |
Levée dOption de Licence par AstraZeneca pour un Virus Oncolytique issu de la Plateforme Invir.IO | | 7945 | |
Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgenes Invir.IO Platform | | 31869 | |
Transgene annonce une levée doption de licence par AstraZeneca pour un virus oncolytique issu de sa plateforme Invir.IO | | 11353 | |
TG4050, First positive clinical data from Phase I clinical trials | | 7945 | |
TG4050, Premiers résultats positifs des essais de Phase I (en français) | | 7945 | |
Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine | | 19620 | |
Transgene et NEC annoncent des premiers résultats positifs des essais de Phase I de TG4050, un vaccin thérapeutique individualisé innovant contre le cancer | | 10085 | |
annonceHome | | 7945 | |
annonceHomeUS | | 7945 | |
TG4050 | | 7945 | |
Icon | | 7945 | |
TG4050 | | 7945 | |
annonce substitut | | 7945 | |
annonce | | 7945 | |
Careers | | 7945 | |
Annual General Meeting | | 7945 | |
événements et presentations | | 7945 | |
Analysts | | 7945 | |
General | | 7945 | |
Key figures | | 7945 | |
Financial reports | | 7945 | |
Information boursière | | 7945 | |
Financial information | | 7945 | |
Regulated information | | 7945 | |
Publications | | 7945 | |
RH(en) | | 7945 | |
Icon | | 7945 | |
Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 2021 | | 8377 | |
Transgene reports business update and Q3 2021 financial position | | 7945 | |
Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021 | | 8144 | |
Transgene et BioInvent présentent des données précliniques soulignant la forte activité antitumorale du virus oncolytique BT-001 au SITC 2021 | | 8567 | |
Transgene publie sa situation financière et fait un point sur son activité au troisième trimestre 2021 | | 8540 | |
Transgene et BioInvent présenteront des données précliniques sur le virus oncolytique BT-001 au SITC 2021 | | 8188 | |
annonce substitut | | 7945 | |
annonce | | 7945 | |
annonce | | 7945 | |
TG4050 | | 7945 | |
Nous rejoindre | | 7945 | |
esmo | | 7945 | |
esmo2021 | | 7945 | |
bg3 | | 7945 | |
bg2 | | 7945 | |
bg1 | | 7945 | |
Statistiques | | 7945 | |
RH | | 7945 | |
produits : BT-001 | | 7945 | |
produits : TG6002 | | 7945 | |
produits : TG4001 | | 7945 | |
produits : TG4050 | | 7945 | |
Publications | | 7945 | |
techno invirio | | 7945 | |
techno myvac | | 7945 | |
techno Oncolytic viruses | | 7945 | |
techno Therapeutic Vaccines | | 7945 | |
FAQ | | 7945 | |
| | 7945 | |
produits : 5 OVs teaser | | 7945 | |
produits : OVs teaser | | 7945 | |
produits : BT-001 teaser | | 7945 | |
produits : TG6002 teaser | | 7945 | |
produits : TG4001 teaser | | 7945 | |
produits : TG4050 teaser | | 7945 | |
pipeline | | 7945 | |
CORPORATE GOVERNANCE | | 7945 | |
Dr. Laurence ZITVOGEL | | 7945 | |
Sandrine Flory TSGH | | 7945 | |
Maya SAID | | 7945 | |
Alain MÉRIEUX | | 7945 | |
Marie LANDEL | | 7945 | |
Benoît HABERT | | 7945 | |
Dr. Jean-Pierre BIZZARI | | 7945 | |
Antoine BÉRET | | 7945 | |
Jean-Luc BÉLINGARD | | 7945 | |
conseil | | 7945 | |
Philippe ARCHINARD | | 7945 | |
Gaëlle STADTLER | | 7945 | |
John FELITTI | | 7945 | |
Steven Bloom | | 7945 | |
Jean-Philippe Del | | 7945 | |
Maud BRANDELY | | 7945 | |
Christophe ANCEL | | 7945 | |
Eric QUÉMÉNEUR | | 7945 | |
Hedi Ben Brahim | | 7945 | |
Management committee | | 7945 | |
Home news plugin | | 7945 | |
innovation box | | 7945 | |
TG4001 box | | 7945 | |
myvac-box | | 7945 | |
invirio-box | | 7945 | |
videos | | 7945 | |